Physician profile
Eric J Eross
NPI 1063574572
$778,311.96
in general payments reported to CMS, 2019-2025
24 companies · $180K in 2025
The $180K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $131K · 2021: $143K · 2022: $207K · 2023: $35K · 2024: $23K · 2025: $180K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $109K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Consulting Fee: $43K · Travel and Lodging: $17K · Food and Beverage: $5,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $108,848.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,342.00 |
| Consulting Fee | $42,970.76 |
| Travel and Lodging | $17,473.89 |
| Food and Beverage | $5,660.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $142,441.73 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $121,626.89 | 2020-2021 | |
| Axsome Therapeutics, INC. | $106,811.95 | 2025 | Symbravo |
| Lilly USA, LLC | $91,339.48 | 2019-2024 | Reyvow, Emgality |
| Abbvie INC. | $68,432.31 | 2021-2025 | |
| Amgen INC. | $57,537.23 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $53,688.40 | 2022-2023 | Trudhesa |
| Lundbeck LLC | $51,762.75 | 2020-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $28,309.42 | 2019-2025 | Ajovy |
| Allergan, INC. | $27,889.60 | 2020-2021 | |
| Pfizer INC. | $21,240.97 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $4,400.31 | 2019 | |
| Supernus Pharmaceuticals, INC. | $2,542.24 | 2020 | |
| Scilex Pharmaceuticals INC. | $88.05 | 2023-2024 | Ztlido |
| Horizon Therapeutics Plc | $46.97 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $32.42 | 2021-2024 | Eterna |
| Upsher-Smith Laboratories LLC | $28.86 | 2022-2023 | |
| Tempus Ai, INC | $28.41 | 2024 | Tempus Pixel |
| Boston Scientific Corporation | $15.05 | 2021 | |
| Tonix Medicines, INC. | $14.84 | 2025 | Zembrace Symtouch |
| Nevro Corp. | $13.83 | 2022 | |
| Currax Pharmaceuticals LLC | $12.99 | 2020 | |
| Impel Pharmaceuticals LLC | $6.43 | 2024 | Trudhesa |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Eross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.